

13th Asia-Pacific Oncologists Annual Meeting

October 17-19, 2016 Kuala Lumpur, Malaysia

Frontiers of Next Generation Sequencing in Translational Oncology

Kahlil Lawless

Product Marketing Manager, Illumina Inc, Singapore

The steep drop in price and increases in output of Next Generation Sequencing (NGS), as well as the emergence of new methods and studies, are at the forefront in changing our understanding and management of cancer. Kahlil Lawless from Illumina delves into the opportunities and challenges of applying NGS to oncology practice, and highlights recent publications around large-scale initiatives, innovative techniques, and the promise of precision medicine. Next Generation Sequencing (NGS) technologies continue to deliver new insights into cancer biology, and these are being increasingly leveraged to develop new therapies and testing methods to support management of cancer. We review some recent translational studies where Illumina NGS has been used, and evaluate the potential challenges and benefits associated with routine adoption of these methods in practice.

Biography

Kahlil Lawless studied Biomedical Science at Victoria University of Wellington, New Zealand. Following a scholarship at Australia National University he conducted research for the state government of Victoria in Melbourne, and now works for Illumina in the South-Asia Pacific Region as a Product Marketing Manager with a focus on the use of genomics in Oncology.

klawless@illumina.com

Notes: